Core Viewpoint - The company has raised its revenue forecast for 2025 by 5.0% to 12.6 billion yuan, and its net profit forecast for 2026 has been increased by 274% to 6.68 billion yuan due to collaboration with Takeda, with a new net profit forecast for 2027 set at 4.14 billion yuan [1] Group 1 - The company forecasts a product revenue of approximately 11.9 billion yuan for 2025, representing a year-on-year growth of about 45%, with Q4 product revenue expected to be around 3.3 billion yuan, showing over 60% growth [2] - The company's product revenue has surpassed 10 billion yuan for the first time, driven by innovative products, with the oncology product portfolio expanding to 13 products by 2025 [3] - The company has seven products entering the national medical insurance directory for 2025, which will be implemented in 2026, indicating strong commercial momentum [4] Group 2 - The company is focusing on the continuous realization of innovative molecules like IBI363 and its internationalization process, with significant collaboration with Takeda worth 10 billion USD announced in October 2025 [5] - The company expects substantial profit growth in 2026 due to the anticipated progress in global development of IBI363 and other clinical trials [5]

Market Overview - The Hang Seng Index closed down 325 points, a weekly decline of 827 points, marking a 3.02% drop [3][4] - The index opened lower by 530 points, reaching a low of 26,295 points before stabilizing [3] - The total market turnover for the day was 247.865 billion HKD, with a net inflow of 14.859 billion HKD from northbound trading [3] Company News - **Xinda Biopharmaceuticals** entered a strategic partnership with Eli Lilly to advance global research and development of innovative drugs in oncology and immunology, receiving an upfront payment of 350 million USD (approximately 2.73 billion HKD) [12] - **Meitu Inc.** expects adjusted net profit growth of 60% to 66% for the fiscal year ending December 2025, driven by rapid growth in its imaging and design products segment [13] - **Jiaxin International** anticipates a turnaround with a net profit of approximately 300 to 340 million HKD for the year ending last December, compared to a loss of 173 million HKD in the previous year [14] - **Color Star Technology** expects a net loss of 15 million HKD for the year ending last December, a reversal from a net profit of 132 million HKD in 2024, primarily due to a 45% decrease in revenue [15] Economic Indicators - Hong Kong's official foreign exchange reserves increased by 7.7 billion USD to 435.6 billion USD at the end of January, equivalent to over five times the currency in circulation [8] - China's foreign exchange reserves rose for the sixth consecutive month, reaching 3.399 trillion USD, with gold reserves increasing for 15 months [10]

Core Viewpoint - Junshi Biosciences (01877) has seen a stock price increase of over 5%, currently trading at 21.8 HKD, with a transaction volume of 39.91 million HKD. The company announced expectations for significant revenue growth and reduced losses for the fiscal year 2025 [1]. Group 1: Financial Projections - The company anticipates achieving an annual revenue of approximately 2.5 billion RMB in 2025, representing a year-on-year growth of about 28.32% [1]. - Expected R&D expenses for 2025 are projected to be around 1.353 billion RMB, reflecting a year-on-year increase of approximately 6.10% [1]. - The net loss attributable to shareholders for 2025 is estimated to be around 873 million RMB, which is a reduction of about 31.85% compared to the previous year [1]. - After excluding the impact of share-based payments, the net loss attributable to shareholders is expected to be approximately 799 million RMB, indicating a year-on-year decrease of about 37.62% [1]. - The net loss attributable to shareholders, after excluding non-recurring gains and losses, is projected to be around 985 million RMB, which is a reduction of approximately 23.64% year-on-year [1]. Group 2: Product Performance - The company's revenue growth during the reporting period is primarily driven by increased sales of commercialized drugs compared to the previous year [2]. - The core product, Toripalimab injection (brand name: Tuoyi), has seen a significant increase in sales revenue in the domestic market year-on-year [2]. - As of the announcement date, Tuoyi has been included in the national medical insurance catalog for all 12 approved indications in mainland China, making it the only anti-PD-1 monoclonal antibody drug in the catalog for the treatment of renal cancer, triple-negative breast cancer, and melanoma [2].

Core Viewpoint - Junshi Biosciences (01877) is expected to achieve significant revenue growth and a reduction in net losses by 2025, driven by improved commercialization capabilities and cost control measures [1][2]. Group 1: Financial Projections - The company anticipates a revenue of approximately 2.5 billion yuan for the year 2025, representing a year-on-year growth of about 28.32% [1]. - Research and development expenses are projected to be around 1.353 billion yuan in 2025, reflecting a year-on-year increase of approximately 6.10% [1]. - The expected net loss attributable to shareholders for 2025 is around 873 million yuan, which is a reduction of about 31.85% compared to the previous year [1]. - After excluding the impact of share-based payments, the net loss is projected to be approximately 799 million yuan, indicating a decrease of about 37.62% year-on-year [1]. - The net loss attributable to shareholders, after excluding non-recurring gains and losses, is expected to be around 985 million yuan, a reduction of approximately 23.64% compared to the previous year [1]. Group 2: Product Performance - The company's revenue growth during the reporting period is primarily attributed to increased sales of commercialized drugs [2]. - The core product, Toripalimab injection (brand name: Tuoyi®), has seen a significant year-on-year increase in sales revenue in the domestic market [2]. - As of the announcement date, Tuoyi® has been included in the national medical insurance catalog for all 12 approved indications in mainland China, making it the only anti-PD-1 monoclonal antibody in the catalog for the treatment of renal cancer, triple-negative breast cancer, and melanoma [2].

Core Viewpoint - The strategic collaboration between Innovent Biologics and Eli Lilly aims to advance global research and development of innovative drugs in oncology and immunology, with Innovent leading the projects in China while Eli Lilly retains exclusive rights outside Greater China [1]. Group 1: Partnership Details - Innovent Biologics will receive an upfront payment of $350 million and is eligible for up to $8.5 billion in milestone payments related to research, regulatory, and commercialization achievements [1]. - The collaboration marks the seventh partnership between Innovent and Eli Lilly, highlighting a long-standing relationship that has evolved from capital investment to product commercialization [2]. - Innovent has previously collaborated with Eli Lilly on multiple projects, including agreements that set records for cooperation amounts between multinational and local pharmaceutical companies [2][3]. Group 2: Financial Performance - In 2020, Innovent achieved total revenue of 3.844 billion yuan, a year-on-year increase of 266.9%, with product revenue reaching 2.368 billion yuan, a 133.0% increase [3]. - The company anticipates total product revenue of approximately 11.9 billion yuan in 2025, marking a 45% year-on-year growth and the first time surpassing 10 billion yuan in product revenue [7]. - Innovent aims to achieve a product revenue scale of 20 billion yuan by 2027 and plans to advance five core pipelines into global Phase III clinical trials by 2030 [7]. Group 3: Globalization Strategy - Innovent's collaboration model has become a crucial component of its product pipeline, with 18 approved products, many developed through partnerships [6]. - The company is focusing on reducing reliance on external collaborations while enhancing its core R&D capabilities [10]. - Innovent's internationalization journey reflects the broader trend of Chinese innovative pharmaceutical companies transitioning to global markets, emphasizing the need for quality and originality in innovation [10].

来源：科技日报 科技日报记者 李禾 斐缦生物董事总经理陈欣伟说："斐缦全新自研的可控自组装技术平台是胶原突破性的精准进化力，让 自组装过程被设计、可控制。"没有秩序的胶原蛋白是一堆散沙，容易被代谢、被降解，有秩序的胶原 蛋白才是支撑起皮肤弹性的"钢筋铁骨"。可控自组装技术的最大魅力就是实现了胶原蛋白的"定制化"， 完成从形成结构到形成特定需要结构的技术跨越。 复旦大学生物医学工程与技术创新学院青年研究员、上海皮肤健康概念验证中心执行主任马彦云博士围 绕活性胶原的结构特征、作用机制以及多场景应用价值，阐述了系统性研究结论与实践验证成果。据 悉，斐缦生物与复旦大学正在进行胶原蛋白的校企联合研究。双方将以胶原技术为支撑，围绕皮肤修 复、黏膜修复、再生医学乃至营养学等多个场景持续探索。 （受访者供图） 近日，"智构胶原·有序新生"2026斐缦生物"可控自组装技术"生态发布会在吉林长春举办。斐缦生物凭 借全新自研的可控自组装技术平台，首次实现胶原纤维的"定制化"，并建立了全链路品质管控体系。 ...

Core Viewpoint - The strategic collaboration between Innovent Biologics and Eli Lilly aims to advance the global research and development of innovative drugs in oncology and immunology, marking a significant milestone in their long-term partnership [1] Group 1: Financial Aspects - Innovent Biologics received an upfront payment of $350 million as part of the agreement [1] - The company is eligible for up to approximately $8.5 billion in milestone payments related to research, regulatory, and commercialization achievements [1] - Innovent Biologics retains the rights to all products in Greater China while Eli Lilly secures exclusive global development and commercialization rights outside this region [1] Group 2: Strategic Collaboration - This agreement represents the seventh collaboration between Innovent Biologics and Eli Lilly, further deepening their productive partnership [1] - The collaboration leverages Innovent's established antibody technology platform and efficient clinical capabilities to lead projects from drug discovery to clinical concept verification in China [1] - Eli Lilly will benefit from the global exclusive development and commercialization rights for the relevant projects outside Greater China [1]

Core Viewpoint - Cinda Biologics has entered into a strategic partnership with Eli Lilly to advance global research and development of innovative drugs in oncology and immunology, which is expected to enhance their long-term collaboration and drive growth in the biopharmaceutical sector [1] Group 1: Financial Terms of the Agreement - Cinda Biologics will receive an upfront payment of $350 million from Eli Lilly [1] - The agreement includes potential milestone payments totaling up to approximately $8.5 billion, contingent upon achieving specific development, regulatory, and commercialization milestones [1] - Cinda Biologics is entitled to a tiered sales share from net sales outside Greater China for each product [1] Group 2: Collaborative Efforts and Responsibilities - This partnership marks the seventh collaboration between Cinda Biologics and Eli Lilly, further deepening their productive relationship [1] - Cinda Biologics will leverage its established antibody technology platform and efficient clinical capabilities to lead the projects from drug discovery to clinical concept verification (completion of Phase II trials) [1] - Eli Lilly will obtain exclusive global development and commercialization rights for the relevant projects outside Greater China, while Cinda Biologics retains all rights within Greater China [1]

Group 1 - Shanghai is actively expanding high-level opening-up and placing greater emphasis on technological innovation as part of its "14th Five-Year Plan" [2] - The biopharmaceutical industry is one of the three key leading industries in Shanghai, with Boehringer Ingelheim being a global leader in biopharmaceuticals [2] - Shanghai aims to create a long-term, stable, transparent, and predictable development environment to provide new opportunities for global enterprises [2] Group 2 - Boehringer Ingelheim is committed to increasing its innovation investment in Shanghai and collaborating with partners to deepen innovation and research and development [3] - Carl Zeiss AG is focused on leveraging its brand, professional, and innovation advantages to enhance its regional headquarters' functions in Shanghai [3] - Both companies are encouraged to participate in building a more competitive industrial ecosystem and to achieve breakthrough innovations in global markets [3]

Core Insights - The company announced that its biomanufacturing business will complete the capacity construction of its first industrialization project by 2025 and is expected to commence production in the first quarter of 2026 [1] - The company has established partnerships with downstream customers and is actively engaging with them [1] - The company's quadrivalent meningococcal vaccine is currently in Phase III clinical trials, and it will strictly adhere to national drug registration procedures and regulations [1]